{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.2-dev",
    "document_metadata": {
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved",
      "licenses": "CC BY 4.0",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-b peptide and s levels: target engagement, tolerability and pharmacokinetics in humans",
      "version": "0.1.0",
      "authors": "Lingling Xu",
      "description": ""
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/3c85897632afa791ac78fb3aa2e392963ab155b1/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$",
      "PUBCHEM": "^\\d+$"
    },
    "namespaces_uncached": [],
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "annotation_pattern": {
      "Species": "^\\d+$",
      "MeasurementValue": ".*",
      "MeasurementRangeLower": ".*",
      "MeasurementRangeUpper": ".*",
      "Page": ".*",
      "Figure": ".*",
      "ArticleCompoundNumber": ".*"
    },
    "annotation_list": {
      "MeasurementType": [
        "CSF concentration",
        "IC50",
        "brain concertration",
        "dose",
        "plasma concentration"
      ],
      "MeasurementUnits": [
        "mg",
        "μM"
      ],
      "MeasurementRelation": [
        "=",
        "~"
      ]
    },
    "path": "maccecchini2012.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "PUBCHEM",
      "name": "11249342",
      "id": "a46738b941738ccd9850de2ee68d8707ed2370bd9a91e2bde28f56a100b25e932132c325e594949b4600c31fca28105cfb8c05197d03d2cb1cac44c0983130ad"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "sAPP-alpha",
      "id": "418c49e0c3ffa3351f60cd21b4b10a7b0350af5edd981d17c3abd3d60a03d9e431358632bfd8f8921627ff026ccddce4156279ef19243074e88cd4a76d940322"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "sAPP-beta",
      "id": "5f1801ec0c9b3dadc727542d1599d75009fa94146d16089405e295556502387876deb8a7703f4c9d2d907e27459dcff4420cee93532d3263747f34d122592482"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "C3",
      "id": "0edfd55c060706048fdcf977108c333ff8efc8adbf002b1c9dde5c3bd1dcc787db0397fd423224707a5e691d14afdb25dba7beaabd44b15dc8dff5d21c5034c5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CCL2",
      "id": "0ffaf8edf9d1f6deb96f353ad12fccb2cc8250da79451f2fd3f673b99f190ead3987d4e96df92f61da68955493c39c3f56507db2adeefcdf744f6c8cba24e84a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CFH",
      "id": "fc7eadb98840a209ec88e805b2165b4815f7d4408620a0f92fb74c929fb011a51bba58249ab92ed96529213c91f569713f3d62f6e1023484cfdec738def2efbf"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHI3L1",
      "id": "8e69d1d4413821f768906b0b5de2d23722027049c04d9205f76c1b5cc2cd8260f15bc803cd52959ecf678b4ddc9a407149e1d77d8af7e704af782cd1ebb0c40a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Nausea",
      "id": "76613aad01556d20038f32be68dc0dee4ca1a032b70d7b64a967daf007cf535bce562835b50af6a482040811d773d93cdd8732eeb2aa137f19396665b213da79"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Vomiting",
      "id": "0997523c73935a3a0ed39198a04b8abd904fc14fba9168590d27722b6293c8810b1b808504dc1be4768657a34fe3a9429658035700a0200ec2397f6868a8481d"
    }
  ],
  "links": [
    {
      "line": 98,
      "relation": "increases",
      "evidence": "A 160 mg dose was associated with an increased incidence of nausea and vomiting (four subjects were nauseous and three vomited)",
      "citation": {
        "type": "PubMed",
        "reference": "22791904",
        "name": "Journal of neurology, neurosurgery, and psychiatry",
        "title": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "volume": "83",
        "pages": "894-902",
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "last": "Greig NH",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ]
      },
      "annotations": {
        "Page": {
          "896": true
        },
        "Figure": {
          "2A": true
        },
        "ArticleCompoundNumber": {
          "1": true
        },
        "MeasurementType": {
          "dose": true
        },
        "MeasurementUnits": {
          "mg": true
        },
        "MeasurementValue": {
          "160": true
        }
      },
      "source": 0,
      "target": 9,
      "key": "f1bbc15445206ec859e667cf9f799bb2a95bd73eabfe53d8fbbeeefdfcf11a2d9abc0be11e8a7f70cde0f43fc05b3e7e5122c9a3deb51e2e7613df021b30ca74"
    },
    {
      "line": 110,
      "relation": "causesNoChange",
      "evidence": "Posiphen 80 mg was determined as the no observed adverse effect level (table 1).",
      "citation": {
        "type": "PubMed",
        "reference": "22791904",
        "name": "Journal of neurology, neurosurgery, and psychiatry",
        "title": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "volume": "83",
        "pages": "894-902",
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "last": "Greig NH",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ]
      },
      "annotations": {
        "Page": {
          "896": true
        },
        "ArticleCompoundNumber": {
          "1": true
        },
        "MeasurementType": {
          "dose": true
        },
        "MeasurementUnits": {
          "mg": true
        },
        "MeasurementValue": {
          "80": true
        }
      },
      "source": 0,
      "target": 9,
      "key": "c5dac04a7e49ac9f8974db2b6863861e91708dbed293135bcd8dc4b8a50ea0f91f4e42de03394cc48d818308e67b6d59f01cb0bfe2a8b3a59486293d03ab4181"
    },
    {
      "line": 99,
      "relation": "increases",
      "evidence": "A 160 mg dose was associated with an increased incidence of nausea and vomiting (four subjects were nauseous and three vomited)",
      "citation": {
        "type": "PubMed",
        "reference": "22791904",
        "name": "Journal of neurology, neurosurgery, and psychiatry",
        "title": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "volume": "83",
        "pages": "894-902",
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "last": "Greig NH",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ]
      },
      "annotations": {
        "Page": {
          "896": true
        },
        "Figure": {
          "2A": true
        },
        "ArticleCompoundNumber": {
          "1": true
        },
        "MeasurementType": {
          "dose": true
        },
        "MeasurementUnits": {
          "mg": true
        },
        "MeasurementValue": {
          "160": true
        }
      },
      "source": 0,
      "target": 10,
      "key": "4de8f28a401fa59030b1163640399c210a2e5b3e78a571449074ca3d4a33cbb6fa5325fd5d0529755ad0bf3feb0b657c3884ffaf6a3ba017622cee829068277f"
    },
    {
      "line": 111,
      "relation": "causesNoChange",
      "evidence": "Posiphen 80 mg was determined as the no observed adverse effect level (table 1).",
      "citation": {
        "type": "PubMed",
        "reference": "22791904",
        "name": "Journal of neurology, neurosurgery, and psychiatry",
        "title": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "volume": "83",
        "pages": "894-902",
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "last": "Greig NH",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ]
      },
      "annotations": {
        "Page": {
          "896": true
        },
        "ArticleCompoundNumber": {
          "1": true
        },
        "MeasurementType": {
          "dose": true
        },
        "MeasurementUnits": {
          "mg": true
        },
        "MeasurementValue": {
          "80": true
        }
      },
      "source": 0,
      "target": 10,
      "key": "dbf8d687caba298102d20e33998e96ac90629b08c93b640f3a2fbe9206c7139bf7d0c76579ee630c13843dcb9e30a6240e85e5cb7fad184cb19447836d40e149"
    },
    {
      "line": 119,
      "relation": "decreases",
      "evidence": "Specifically, Posiphen lowered sAPPa and sAPPb levels by \u000159.9% and \u000157.7%, respectively, assessed by the AlpaLisa assay, and by \u000134.1% and \u000134%, respectively, assessed by the MSD assay, in accordance with Posiphen’s proposed mechanism of action to inhibit APP expression.",
      "citation": {
        "type": "PubMed",
        "reference": "22791904",
        "name": "Journal of neurology, neurosurgery, and psychiatry",
        "title": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "volume": "83",
        "pages": "894-902",
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "last": "Greig NH",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ]
      },
      "annotations": {
        "Page": {
          "899": true
        },
        "ArticleCompoundNumber": {
          "1": true
        }
      },
      "source": 0,
      "target": 1,
      "key": "2df132eba0ba8278603cd03b89838ca5bd75308d89bd281c005fdbbf058d581bdf542c450fd230982020dbfd1f2cb5aceb14cc709e0da3ed2a60501c04a01322"
    },
    {
      "line": 120,
      "relation": "decreases",
      "evidence": "Specifically, Posiphen lowered sAPPa and sAPPb levels by \u000159.9% and \u000157.7%, respectively, assessed by the AlpaLisa assay, and by \u000134.1% and \u000134%, respectively, assessed by the MSD assay, in accordance with Posiphen’s proposed mechanism of action to inhibit APP expression.",
      "citation": {
        "type": "PubMed",
        "reference": "22791904",
        "name": "Journal of neurology, neurosurgery, and psychiatry",
        "title": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "volume": "83",
        "pages": "894-902",
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "last": "Greig NH",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ]
      },
      "annotations": {
        "Page": {
          "899": true
        },
        "ArticleCompoundNumber": {
          "1": true
        }
      },
      "source": 0,
      "target": 2,
      "key": "4b9a24d2a70bc50119f597ac99091ddb80d54df6d1266235f340603606254352a5de6cd54d9a6d7865930708bfa777dc8a0845f190ad982e85f2a9ff2f42299e"
    },
    {
      "line": 123,
      "relation": "decreases",
      "evidence": "In addition, Posiphen significantly reduced levels of t-s (\u000174.1%, as assessed by the Innogenetics assay and \u000146.2%, as assessed by the AlphaLisa assay) and p-s (\u000161%, as assessed by the Innogenetics assay).",
      "citation": {
        "type": "PubMed",
        "reference": "22791904",
        "name": "Journal of neurology, neurosurgery, and psychiatry",
        "title": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "volume": "83",
        "pages": "894-902",
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "last": "Greig NH",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ]
      },
      "annotations": {
        "Page": {
          "899": true
        },
        "ArticleCompoundNumber": {
          "1": true
        }
      },
      "source": 0,
      "target": 7,
      "key": "a488bfcf8218aa73e56e0acd9dc743e892c4d3ba9a673dab11e45a19115c88ade968151d3e566ff76d400ba0904e7fb40376e89918fd54c66c055aa7f86abefd"
    },
    {
      "line": 124,
      "relation": "decreases",
      "evidence": "In addition, Posiphen significantly reduced levels of t-s (\u000174.1%, as assessed by the Innogenetics assay and \u000146.2%, as assessed by the AlphaLisa assay) and p-s (\u000161%, as assessed by the Innogenetics assay).",
      "citation": {
        "type": "PubMed",
        "reference": "22791904",
        "name": "Journal of neurology, neurosurgery, and psychiatry",
        "title": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "volume": "83",
        "pages": "894-902",
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "last": "Greig NH",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ]
      },
      "annotations": {
        "Page": {
          "899": true
        },
        "ArticleCompoundNumber": {
          "1": true
        }
      },
      "source": 0,
      "target": 8,
      "key": "76410f1fa7b0c23262df00c6da0c23643a246d36c2a5c988fb9616438586c6a2eb08c401d1d2549d0d7a0ac86d0fdca99f96f88fe4ef93fa98ce4a73e7d4a708"
    },
    {
      "line": 127,
      "relation": "decreases",
      "evidence": " A significant lowering of pro-inflammatory, C3 (\u000186.9%) and microglial activation markers, MCP-1 (\u000187.5%) and YKL-40 (\u000172.7%), was evident.",
      "citation": {
        "type": "PubMed",
        "reference": "22791904",
        "name": "Journal of neurology, neurosurgery, and psychiatry",
        "title": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "volume": "83",
        "pages": "894-902",
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "last": "Greig NH",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ]
      },
      "annotations": {
        "Page": {
          "899": true
        },
        "ArticleCompoundNumber": {
          "1": true
        }
      },
      "source": 0,
      "target": 3,
      "key": "1e4773816a549de7bdd9318c9762ec78e04c338d8e45ef4355202c5b68667a8bec7fad36a8ee6ad1b35ec3855df84d79949927ed76c62609cf7a18623482d9fd"
    },
    {
      "line": 128,
      "relation": "decreases",
      "evidence": " A significant lowering of pro-inflammatory, C3 (\u000186.9%) and microglial activation markers, MCP-1 (\u000187.5%) and YKL-40 (\u000172.7%), was evident.",
      "citation": {
        "type": "PubMed",
        "reference": "22791904",
        "name": "Journal of neurology, neurosurgery, and psychiatry",
        "title": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "volume": "83",
        "pages": "894-902",
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "last": "Greig NH",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ]
      },
      "annotations": {
        "Page": {
          "899": true
        },
        "ArticleCompoundNumber": {
          "1": true
        }
      },
      "source": 0,
      "target": 4,
      "key": "4401b8d1038a34f992e189a67b27907f942b2d7c03601dfd2de12a4033c1b437561b52e9e9f343c86f7d458a5dda1f6d6dd49477ccb5aebdd113b8e09ea070b8"
    },
    {
      "line": 129,
      "relation": "decreases",
      "evidence": " A significant lowering of pro-inflammatory, C3 (\u000186.9%) and microglial activation markers, MCP-1 (\u000187.5%) and YKL-40 (\u000172.7%), was evident.",
      "citation": {
        "type": "PubMed",
        "reference": "22791904",
        "name": "Journal of neurology, neurosurgery, and psychiatry",
        "title": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "volume": "83",
        "pages": "894-902",
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "last": "Greig NH",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ]
      },
      "annotations": {
        "Page": {
          "899": true
        },
        "ArticleCompoundNumber": {
          "1": true
        }
      },
      "source": 0,
      "target": 6,
      "key": "dfc8de5b22becdc6d56064ef69799a299b534a0216b24296945832a4561a38f44ebafe97c27a5bc3953f7d369c09d7d43bafeddfb7202c165363b8ba61ed9ad5"
    },
    {
      "line": 132,
      "relation": "causesNoChange",
      "evidence": "and the complement control protein, factor H, were unaffected by Posiphen (\u000126.1% and +23.7%, respectively).",
      "citation": {
        "type": "PubMed",
        "reference": "22791904",
        "name": "Journal of neurology, neurosurgery, and psychiatry",
        "title": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "volume": "83",
        "pages": "894-902",
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "last": "Greig NH",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ]
      },
      "annotations": {
        "Page": {
          "899": true
        },
        "ArticleCompoundNumber": {
          "1": true
        }
      },
      "source": 0,
      "target": 5,
      "key": "cf37940954c5167b7630b24dab7a651eada9cdf71b9266920516166152b323634cc1d9f0e4a854968a66242c359ad20c90d77673366d46dcef4de41871279357"
    },
    {
      "relation": "hasVariant",
      "source": 7,
      "target": 8,
      "key": "c4e71f1866eab20795e7e1d4b54fe09effb8b376e41712f8a130fe5192e07d83b0749cc2e2297b62cbea4bb7b1033909ea6d6423fa06166cb07543cee4249d48"
    }
  ]
}